# OnCo record lazertinib (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/lazertinib/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "lazertinib" ;
  schema:name "Lazertinib"@en ;
  schema:description "A third-generation EGFR pill used together with amivantamab as the first regimen to beat osimertinib in EGFR-mutant lung cancer."@en ;
  schema:url <https://onco.cc/drugs/lazertinib/> ;
  schema:dateModified "2026-09-06"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Lazertinib> ;
  owl:sameAs <http://www.wikidata.org/entity/Q105337288> ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Lazertinib>, <https://www.nice.org.uk/guidance/ta1122> ;
  onco:status "approved" ;
  onco:modality "Small-molecule kinase inhibitor (EGFR)" ;
  schema:alternateName "Lazcluze" ;
  onco:approval "US 2024: First-line EGFR exon 19 del / L858R NSCLC with amivantamab", "EU 2025: 1L EGFR-mutant NSCLC with amivantamab; 20 Jan 2025", "England (NICE) 2026: Untreated advanced EGFR mutation-positive non-small-cell lung cancer (exon 19 deletion or L858R), with amivantamab" ;
  onco:related <https://onco.cc/biomarkers/egfr-l858r/> ;
  onco:cancers <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/egfr-mutant-nsclc/>, <https://onco.cc/cancers/lung-cancer/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:targets <https://onco.cc/targets/egfr/> ;
  onco:drugs <https://onco.cc/drugs/amivantamab/> ;
  onco:companies <https://onco.cc/companies/johnson-johnson/> ;
  onco:trials <https://onco.cc/trials/mariposa/>, <https://onco.cc/trials/nct05388669/>, <https://onco.cc/trials/nct05498428/>, <https://onco.cc/trials/nct05663866/>, <https://onco.cc/trials/nct06667076/>, <https://onco.cc/trials/nct07586202/>, <https://onco.cc/trials/nct06120140/>, <https://onco.cc/trials/nct04988295/>, <https://onco.cc/trials/nct05541822/> .